Jonathan Rubin
Director Técnico/Científico/I+D en SUPERNUS PHARMACEUTICALS, INC. .
Fortuna: 2 M $ al 30/04/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Jack Khattar | M | 62 | 19 años | |
Charles Newhall | M | 79 | 19 años | |
Georges Gemayel | M | 64 | 9 años | |
John Siebert | M | 84 | 13 años | |
Frederick Hudson | M | 78 | 14 años | |
Carrolee Barlow | M | 60 | 6 años | |
Padmanabh P. Bhatt | M | 66 | 19 años | |
Frank Mottola | M | 52 | 19 años | |
Bethany Sensenig | F | 48 | 1 años | |
Timothy Dec | M | 66 | 3 años | |
Kevin T. Anderson | M | 61 | 12 años | |
Bryan A. Roecklein | M | - | 9 años | |
Todd Horich | M | - | 6 años | |
Taylor Raiford | M | - | 9 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Udi Gilboa | M | 57 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 6 años |
David Baker | M | 60 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 3 años |
Yuval Yanai | M | 71 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 1 años |
Joao Siffert | M | 60 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | - |
Arieh Ben-Yosef | M | 71 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 3 años |
Tomer Berkovitz | M | 44 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 4 años |
Amir Efrati | M | 50 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | - |
Tami Martin | F | 68 | 16 años | |
James Kelly | M | 58 | 1 años | |
Stefan Schwabe | M | 72 | 8 años | |
Hagit Marchaim | M | - |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | - |
Orli Tori | M | - |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | - |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 17 | 65.38% |
Israel | 9 | 34.62% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Jonathan Rubin
- Red Personal